NCT04331041View on ClinicalTrials.gov

Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

August 24, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

April 30, 2027

Conditions
Pancreas CancerCancer of the PancreasPancreas Adenocarcinoma
Interventions
DEVICE

Adaptive stereotactic body radiation therapy

"* Will be administered using MRIdian and Ethos~* 50 Gy in 5 fractions"

DRUG

Defactinib

-Oral drug 400 mg twice a day

PROCEDURE

Tumor biopsy

-Baseline and 12-14 weeks after end of SBRT (or at time of surgery)

PROCEDURE

Research blood draw

-Baseline, 6-8 weeks after the end of SBRT, and 12-14 weeks after the end of SBRT

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Verastem, Inc.

INDUSTRY

lead

Washington University School of Medicine

OTHER